SCHEMBL2851890

SCHEMBL2851890

NC(=O)c1cc(-c2cccnc2)n[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP3A4 P08684 1/20 0.61
ALK Q9UM73 1/20 0.58
CYP2D6 P10635 1/20 0.57
CYP2A6 P11509 1/20 0.57
CYP2C9 P11712 1/20 0.57
CYP2B6 P20813 1/20 0.57
CYP2C19 P33261 1/20 0.57
HDAC3 O15379 1/20 0.56
HDAC4 P56524 1/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC7 Q8WUI4 1/20 0.56
HDAC2 Q92769 1/20 0.56
HDAC10 Q969S8 1/20 0.56
HDAC11 Q96DB2 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
HDAC9 Q9UKV0 1/20 0.56
HDAC5 Q9UQL6 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1816813 0.86 TP53 (0.73) ALDH1A1CYP1A2CYP3A4ALKCYP2D6
SCHEMBL2789578 0.83 TP53 (0.74) ALDH1A1TP53PIM1SCN9ACHEK1
SCHEMBL4789868 0.82 CCNC (0.54) ALDH1A1HDAC3HDAC4HDAC1HDAC7
SCHEMBL13710596 0.81 SCN9A (0.55) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL11229356 0.81 ALDH1A1 (0.56) ALDH1A1CYP1A2CYP3A4ALKCYP2D6
SCHEMBL1816625 0.77 ALPL (0.64) ALDH1A1CYP1A2CYP3A4ALKCYP2D6
SCHEMBL20661049 0.77 TP53 (0.51) ALDH1A1TP53PIM1SCN9ACHEK1
SCHEMBL18726294 0.77 SCN9A (0.57) TP53PIM1SCN9ATACR3CHEK1
SCHEMBL2845103 0.77 PLA2G10 (0.52) ALDH1A1TP53
SCHEMBL29444426 0.77 SCN9A (0.57) TP53PIM1SCN9ACHEK1RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS WYETH (US) 2010-05-27 US disclosed
US-20100029606-A1 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF WYETH (US) 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029606-A1 MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF CHRNA7, CHRNA2, CHRNA6 ALDH1A1 1232/4885CYP1A2 1261/4885CYP3A4 2371/4885
US-20100130474-A1 ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR INHIBITORS CHRNA7, CHRNA6, CHRNA2 ALDH1A1 2163/4885CYP1A2 2584/4885CYP3A4 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.